Kingsley Capital Partners
Kingsley Capital Partners LLP is a private equity and venture capital firm based in London, United Kingdom, with additional offices in Hong Kong, Istanbul, Santa Monica, Zürich, and Seoul. Founded in 2011, the firm specializes in growth equity and various investment strategies including acquisitions, shareholder liquidity, and management buyouts. Kingsley Capital focuses on sectors such as consumer and retail, healthcare and life sciences, industrial and business services, and technology, media, and telecommunications. The firm seeks to invest between £5 million and £200 million in equity, taking both minority and majority stakes, and often prefers to act as a sole or lead investor. It emphasizes a collaborative approach with management teams to generate strong risk-adjusted returns and may exit investments through public offerings, trade sales, or strategic mergers. With a strong backing from family offices and institutional investors, Kingsley Capital Partners leverages its extensive market research and industry relationships to support the growth of its partner companies.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
6 past transactions
QuantifiedESG
Series A in 2022
QuantifiedESG is a company that specializes in developing assessment and rating tools focused on environmental, social, and governance (ESG) evaluations. Its platform quantitatively analyzes various social and environmental risk factors, producing detailed ESG evaluation reports. These reports assess the management of business and asset risks, allowing clients to evaluate the sustainability of their supply chains. By providing objective insights into ESG performance, QuantifiedESG supports businesses in making informed decisions regarding sustainable practices and risk management.
Spring Fibre
Seed Round in 2019
Spring Fibre operates fiber optic networks in the United Kingdom to deliver high-speed internet, focusing on underserved and hard-to-reach areas. It provides wholesale access to fiber infrastructure, building gigabit networks designed for maximum uptime and robust backup connectivity for its customers.
Atlas Tower Group
Seed Round in 2018
Atlas Tower Group is a wireless infrastructure solution provider focused on designing and constructing 5G-ready towers and rooftops. The company specializes in acquiring telecommunication sites and offers comprehensive installation and integration services for active infrastructure. By addressing the needs of multiple tenants, Atlas Tower Group enables mobile network operators to meet the increasing demand for coverage and capacity, thereby enhancing connectivity in various regions.
Equinox International
Seed Round in 2018
Equinox is a vertically integrated cannabis company specializing in the development of pharmaceutical-grade products. Its portfolio includes cannabis oil, tinctures, tonics, tablets, creams, and lotions, catering to diverse medical needs.
McQueens Flowers
Acquisition in 2017
McQueens Flowers Ltd is a premier floral design company based in London, United Kingdom, with an additional office in New York, New York. Founded in 1991, it specializes in creating bespoke floral arrangements for a variety of clients, including hotels, restaurants, bars, and weddings. The company is known for its commitment to delivering exceptional floral creations that enhance events and occasions. In addition to its design services, McQueens Flowers offers workshops in schools and sells its products online, further expanding its reach and influence in the floral industry. Initially named McQueens Florists Limited, the company rebranded as McQueens Flowers Ltd in October 2017, solidifying its global reputation for quality and creativity.
Oxford Cannabinoid Technologies
Venture Round in 2017
Oxford Cannabinoid Technologies Ltd., established in 2017 and based in Oxford, UK, is a biopharmaceutical company dedicated to researching, developing, and licensing cannabinoid-based compounds and therapies. Its primary focus lies in creating novel treatments for diseases with high unmet medical need, combining cannabinoid medicine with world-class scientific research and drug development. The company's therapeutic areas of interest include inflammatory diseases, oncology, neurological disorders, and pain management.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.